Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of Maryland ...

Involuntary treatment saved me, and I never would have gotten my condition under control without medication. But the mental ...

Researchers at Seoul National University Hospital confirmed that 'Electroconvulsive Therapy (ECT)' causes changes in the ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its ...

Discussion: Given the use of AChEI's in targeted, symptom specific treatment in other neuropsychiatric disorders, it is surprising to find no related literature in schizophrenia patients.

Many researchers believe that schizophrenia can affect a person's ability to smell and how they perceive smells. However, the ...

Scientists now have greater insight into one of Schizophrenia's poorly understood hallmarks — auditory hallucinations.

The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S. living with ...

Cobenfy (xanomeline and trospium chloride) capsules are the first antipsychotic drug approved to target cholinergic receptors ...

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...